Europe Bioprocessing Market
The Europe bioprocessing market was valued at US$ 6,216.50 million in 2023 and is expected to reach US$ 16,803.47 million by 2031; it is estimated to register a CAGR of 13.2% from 2023 to 2031. Growing Biopharmaceutical Industry Drives Europe Bioprocessing Market
In the biopharmaceutical industry, improved bioprocesses are always in demand to address new regulatory requirements, quality control requirements, and production issues in biological products, cell culture titration, and biosimilar production. In recent years, the biopharmaceutical industry has been growing at an unprecedented pace. Biopharmaceutical companies are spending huge sums in R&D to introduce new molecules with enhanced medical and commercial potency for various therapeutic applications. The acceptance of bioprocessing is gradually increasing due to its wide application in research, development, and manufacturing of biologics and biosimilars. Big pharmaceutical companies and contract research organizations are coming up with new medicines and therapy forms to treat a wide range of indications. Further, a strong demand for biologics and biosimilars to treat chronic diseases is, in turn, driving the growth of the biopharmaceutical industry. The biopharmaceutical industry is one of the most significant contributors to the economy. Factors such as increasing biologics approval, growing biosimilar pipeline, rising investment in research activities, and increasing focus on developing affordable biologics are facilitating the growth of the biopharmaceutical industry.
Apart from these, increasing approvals in gene and cell therapies are favoring the bioprocessing market growth. The approved gene therapies are Glybera (to treat lipoprotein lipase deficiency) and Strimvelis (to treat ADA-severe combined immunodeficiency). Thus, the factors mentioned above are increasing the demand for the large-scale production of various therapeutics, thereby facilitating the growth of the bioprocessing market.Europe Bioprocessing Market Overview
Biosimilars introduce competition and increase the affordability of biologics, which ultimately deliver savings and value-added services to support patient care and the healthcare industry. Healthcare professionals can treat more patients with high-quality biologics at reduced cost. Due to the massive potential for cost savings, the German Health Ministry introduced a new law to increase the adoption of biosimilars. Also, a growing number of partnerships among international players boost the market growth in the country. For instance, in November 2020, Hitachi Chemical Advanced Therapeutics Solutions, LLC and apceth Biopharma GmbH expanded their relationship with Bluebird Bio to enter into long-term development and manufacturing services agreements for clinical and commercial supply of multiple therapies, as well as expand commercial drug product manufacturing capacity in Europe for ZYNTEGLO, a one-time gene therapy for transfusion-dependent ?-thalassemia (TDT). Further, the biotechnology sector in Germany exhibits tremendous growth owing to the presence of numerous biotechnology companies, high-tech research labs, and massive funding for research and development. The growth of research and development in biopharmaceuticals and biologics is majorly driven by the adoption of various organic strategies by companies in the healthcare industry. For instance, in June 2021, Rentschler Biopharma expanded its production capacity with a 2,000-liter bioreactor to address the increasing demand for complex antibodies, a class of biopharmaceutical drugs with continued high potential. Likewise, in August 2023, Sartorius, one of the leading suppliers for the biopharmaceutical industry, collaborated with global technology and software leader Emerson to integrate Sartorius's Biostat STR Generation 3 family of bioreactors with Emerson's DeltaVTM distributed control system (DCS). Thus, the biopharmaceutical sector in the country is growing due to increasing R&D expenditure by biopharmaceutical companies. Thus, collaborative research efforts by biopharmaceutical and biotechnology companies in the country influence the market.
Strategic insights for the Europe Bioprocessing provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market. The geographic scope of the Europe Bioprocessing refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
Get more information on this report Europe Bioprocessing Strategic Insights
Get more information on this report Europe Bioprocessing Report Scope
Report Attribute
Details
Market size in 2023
US$ 6,216.50 Million
Market Size by 2031
US$ 16,803.47 Million
Global CAGR (2023 - 2031)
13.2%
Historical Data
2021-2022
Forecast period
2024-2031
Segments Covered
By Product
By Scale of Operation
By Application
By End User
Regions and Countries Covered
Europe
Market leaders and key company profiles
Get more information on this report Europe Bioprocessing Regional Insights
Get more information on this report
Europe Bioprocessing Market Segmentation
The Europe bioprocessing market is categorized into product, scale of operation, process, application, end user, and country.
Based on product, the Europe bioprocessing market is bifurcated into instruments and consumables & accessories. The instruments segment held a larger market share in 2023. Furthermore, the instruments segment is sub segmented into filtration devices, bioreactors, chromatography systems, centrifuge, drying devices, and others. Additionally, the bioreactors subsegment is categorized into pilot scale, full scale, and laboratory scale. Furthermore, the subsegment chromatography systems is segmented into liquid chromatography, gas chromatography, and others. Additionally, the consumables & accessories segment is sub segmented into reagents, cell culture media, chromatography resins, and others.
In terms of scale of operation, the Europe bioprocessing market is bifurcated into commercial operations and clinical operations. The commercial operations segment held a larger market share in 2023.
By process, the Europe bioprocessing market is bifurcated into downstream bioprocess and upstream bioprocess. The downstream bioprocess segment held a larger market share in 2023.
Based on application, the Europe bioprocessing market is categorized into monoclonal antibodies, vaccines, recombinant protein, cell & gene therapy, and others. The monoclonal antibodies segment held the largest market share in 2023.
In terms of end user, the Europe bioprocessing market is categorized into biopharmaceutical companies, contract manufacturing organization, and others. The biopharmaceutical companies segment held the largest market share in 2023.
By country, the Europe bioprocessing market is segmented into Germany, France, Italy, the UK, Spain, and the Rest of Europe. Germany dominated the Europe bioprocessing market share in 2023.
Getinge AB, Thermo Fisher Scientific Inc, Sartorius AG, Corning Inc, Bio-Rad Laboratories Inc, Merck KGaA, 3M Co, Eppendorf SE, Repligen Corp, Entegris Inc, Agilent Technologies Inc, and Cytiva US LLC. are some of the leading companies operating in the Europe bioprocessing market.
The Europe Bioprocessing Market is valued at US$ 6,216.50 Million in 2023, it is projected to reach US$ 16,803.47 Million by 2031.
As per our report Europe Bioprocessing Market, the market size is valued at US$ 6,216.50 Million in 2023, projecting it to reach US$ 16,803.47 Million by 2031. This translates to a CAGR of approximately 13.2% during the forecast period.
The Europe Bioprocessing Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Bioprocessing Market report:
The Europe Bioprocessing Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Bioprocessing Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Bioprocessing Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe Bioprocessing Market
